Exploration of Hydrazide-Based HDAC8 PROTACs for the Treatment of Hematological Malignancies and Solid Tumors

被引:3
|
作者
Zhao, Chunlong [1 ]
Zhang, Jianqiu [1 ]
Zhou, Hangyu [1 ]
Setroikromo, Rita [1 ]
Poelarends, Gerrit J. [1 ]
Dekker, Frank J. [1 ]
机构
[1] Univ Groningen, Groningen Res Inst Pharm GRIP, Dept Chem & Pharmaceut Biol, Antonius Deusinglaan 1, NL-9713 AV Groningen, Netherlands
关键词
HISTONE DEACETYLASE INHIBITORS; E3 UBIQUITIN LIGASE; CELL-DEATH; PROTEIN-DEGRADATION; DISCOVERY; TARGET; COMPLEX; DESIGN; CANCER; POTENT;
D O I
10.1021/acs.jmedchem.4c00836
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
HDAC8 can mediate signals by using its enzymatic or nonenzymatic functions, which are expected to be critical for various types of cancer. Herein, we employed proteolysis targeting chimera (PROTAC) technology to target the enzymatic as well as the nonenzymatic functions of HDAC8. A potent and selective HDAC8 PROTAC Z16 (CZH-726) with low nanomolar DC50 values in various cell lines was identified. Interestingly, Z16 induced structural maintenance of chromosomes protein 3 (SMC3) hyperacetylation at low concentrations and histone hyperacetylation at high concentrations, which can be explained by HDAC8 degradation and off-target HDAC inhibition, respectively. Notably, Z16 potently inhibited proliferation of various cancer cell lines and the antiproliferative mechanisms proved to be cell-type-dependent, which, to a large extent, is due to off-target HDAC inhibition. In conclusion, we report a hydrazide-based HDAC8 PROTAC Z16, which can be used as a probe to investigate the biological functions of HDAC8.
引用
收藏
页码:14016 / 14039
页数:24
相关论文
共 29 条
  • [21] Safety and Efficacy of Bromodomain and Extra-Terminal Inhibitors for the Treatment of Hematological Malignancies and Solid Tumors: A Systematic Study of Clinical Trials
    Sun, Yanli
    Han, Jie
    Wang, Zhanzhao
    Li, Xuening
    Sun, Yanhua
    Hu, Zhenbo
    FRONTIERS IN PHARMACOLOGY, 2021, 11
  • [22] Denosumab for Treatment of Hypercalcemia of Malignancy in Patients with Solid Tumors or Hematological Malignancies Refractory to IV Bisphosphonates: A Single-Arm Multicenter Study
    Hu, Mimi I.
    Gucalp, Rasim
    Insogna, Karl
    Glezerman, Ilya
    Leboulleux, Sophie
    Misiorowski, Waldemar
    Yu, Bennett
    Ying, Wendy
    Yeh, Howard S.
    BLOOD, 2011, 118 (21) : 1064 - 1064
  • [23] A phase I study of the safety and immunogenicity of a multi-peptide personalized genomic vaccine in the adjuvant treatment of solid tumors and hematological malignancies.
    Blazquez, Ana
    Rubinsteyn, Alex
    Kodysh, Julia
    Finnigan, John Patrick
    Marron, Thomas Urban
    Meseck, Marcia
    O'Donnell, Timothy
    Hammerbacher, Jeffrey
    Donovan, Michael J.
    Mahajan, Milind
    Miles, Brett A.
    Irie, Hanna
    Tiersten, Amy
    Tewari, Ashutosh
    Parekh, Samir S.
    Nair, Sujit
    Galsky, Matt D.
    Schadt, Eric E.
    Friedlander, Philip Adam
    Bhardwaj, Nina
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [24] Targeting Enhancer of Zeste Homolog 2 for the Treatment of Hematological Malignancies and Solid Tumors: Candidate Structure-Activity Relationships Insights and Evolution Prospects
    Xia, Juan
    Li, Jingyi
    Tian, Lei
    Ren, Xiaodong
    Liu, Chang
    Liang, Chengyuan
    JOURNAL OF MEDICINAL CHEMISTRY, 2022, 65 (10) : 7016 - 7043
  • [25] Using intentionally mismatched IL-2 activated killer cells (MAKS) for treatment of minimal residual disease in hematological malignancies and metastatic solid tumors
    Slavin, Shimon
    Ackerstein, Aliza
    EXPERIMENTAL HEMATOLOGY, 2008, 36 (07) : S20 - S20
  • [26] A novel topoisomerase I inhibitor based anti-ICAM-1 antibody drug conjugate for the treatment of hematologic malignancies and solid tumors
    Wong, Oi Kwan
    Jackson, David
    Shi, Lei
    Fei, Qi
    Chen, Xiaocheng
    Post, Leonard
    CANCER RESEARCH, 2023, 83 (07)
  • [27] Discovery of Novel Pyrrolo[2,3-d]pyrimidine-based Derivatives as Potent JAK/HDAC Dual Inhibitors for the Treatment of Refractory Solid Tumors
    Liang, Xuewu
    Tang, Shuai
    Liu, Xuyi
    Liu, Yingluo
    Xu, Qifu
    Wang, Xiaomin
    Saidahmatov, Abdusaid
    Li, Chunpu
    Wang, Jiang
    Zhou, Yu
    Zhang, Yingjie
    Geng, Meiyu
    Huang, Min
    Liu, Hong
    JOURNAL OF MEDICINAL CHEMISTRY, 2022, 65 (02) : 1243 - 1264
  • [28] The evolving clinical testing landscape of genomic aberrations in solid tumors and hematological malignancies - Insights from evidence-based reviews for B-ALL and breast, brain, and renal cell neoplasia
    Miron, Patricia M.
    Fang, Min
    CANCER GENETICS, 2020, 244 : 60 - 61
  • [29] HIGH-DOSE CHEMOTHERAPY WITH BLOOD STEM-CELL TRANSPLANTATION IN THE TREATMENT OF SOLID TUMORS AND HEMATOLOGICAL MALIGNANCIES - A ONE-DAY COURSE IN THE CONTINUING-EDUCATION PROGRAM ORGANIZED BY THE TUMOR-CENTER-HEIDELBERG, MANNHEIM, FEBRUARY 1995
    GOLDSCHMIDT, H
    HAAS, R
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 1995, 121 (06) : 383 - 384